Safety and Use of Metoclopramide and Ondansetron in Breastfeeding
Metoclopramide (Maxalon) – Safety Profile
- The Association of Anaesthetists and the American Academy of Pediatrics explicitly approve metoclopramide for use in lactating women, deeming it fully compatible with breastfeeding. 1
- Metoclopramide can increase maternal milk supply by raising serum prolactin through central dopamine antagonism (evidence from expert consensus). 2
- Oral bioavailability is low (~30 %), resulting in minimal infant exposure despite measurable drug levels in breast milk. 3
- At recommended therapeutic doses, there is no requirement to interrupt breastfeeding or to pump‑and‑discard milk. 3
- Because metoclopramide may rapidly augment milk production, a breast pump should be readily available if infant feeding is delayed to prevent engorgement. 1
Ondansetron – Safety Profile
- Ondansetron is considered acceptable for use during breastfeeding even though no human milk transfer studies exist; animal data and pharmacologic properties suggest low transfer. 1
- Based on its physicochemical characteristics, expected milk concentrations are low, supporting its safety in lactating mothers. 1
Clinical Recommendations for Breastfeeding Mothers
Metoclopramide
- Can be prescribed without restriction for nausea, vomiting, or gastroparesis in breastfeeding women. 1
- Typical adult dosing is 10 mg orally three times daily (maximum 30 mg per day). (Praxis guideline) 3
- Clinicians should counsel mothers to monitor for increased milk production and ensure a breast pump is accessible. 1
Ondansetron
- May be used when clinically indicated for nausea and vomiting in breastfeeding mothers, especially if a galactagogue effect is undesirable. 1
- No timing restrictions relative to breastfeeding are required; the drug can be taken at any point without needing to delay feeds. 1
Comparative Antiemetic Options
- Prochlorperazine has low oral bioavailability and is regarded as compatible with breastfeeding. 1
- Cyclizine lacks specific lactation data but is unlikely to cause adverse effects with short‑term use. 1
- Among antiemetics, metoclopramide is the most extensively studied and explicitly endorsed for breastfeeding women. (Praxis guideline) 3
Metoclopramide Use in Post‑partum Lactation
Safety and Compatibility with Breastfeeding
- The Association of Anaesthetists explicitly approves metoclopramide for lactating women, stating it is fully compatible with breastfeeding and does not require interruption of nursing. Guideline approval. 4, 5
- Current evidence shows no increased risk of congenital anomalies or adverse infant effects associated with metoclopramide use during lactation. Observational safety data. 6, 7
Mechanism of Action and Milk‑Production Considerations
- Metoclopramide raises maternal serum prolactin by antagonising central dopamine receptors, a pharmacologic effect that can increase milk supply. Mechanistic evidence. 4, 5
- Because the drug may cause a rapid rise in milk production, mothers should have access to a breast pump if infant feeding is delayed, to prevent engorgement. Clinical recommendation. 4, 5
Adverse Effects and Monitoring
- Extrapyramidal side‑effects (e.g., dystonia, drowsiness, dizziness) can occur; metoclopramide should be discontinued immediately if such symptoms are reported. Safety warning. 6, 7
Alternative Galactogogues
- Domperidone is an alternative galactogogue that may produce fewer central nervous system side‑effects because of limited blood‑brain‑barrier penetration, although its availability is not universal. Comparative observation. 4, 5
Guideline Summary: Domperidone vs Metoclopramide for Anti‑Emetic Use in Lactating Mothers
1. Recommendation Preference
- The American College of Obstetricians and Gynecologists and the American Academy of Pediatrics consider domperidone the preferred anti‑emetic for breastfeeding mothers because it has superior pharmacokinetic properties, fewer central‑nervous‑system side effects, and greater efficacy in increasing milk supply—especially in mothers of preterm infants—while both drugs are listed as compatible with breastfeeding by major guidelines. 8, 9
2. Safety Profile
Domperidone
- Domperidone shows a milk‑to‑plasma ratio of 0.25 and a relative infant dose of 0.01–0.35 %, well below the 10 % safety threshold used to define acceptable infant exposure. 8
- It has 93 % plasma‑protein binding, which limits the amount of free drug that can transfer into breast milk. 8
Metoclopramide
- Metoclopramide has a milk‑to‑plasma ratio of 0.5–4.06 and a relative infant dose of 4.7–14.3 %, exceeding the 10 % safety threshold. 8
3. Regulatory Approval & Compatibility
- The Association of Anaesthetists and the American Academy of Pediatrics explicitly approve metoclopramide as fully compatible with breastfeeding. 8, 9
4. Milk Transfer Data
- The pharmacokinetic data above (milk‑to‑plasma ratios and relative infant doses) demonstrate that domperidone results in markedly lower infant exposure compared with metoclopramide. 8
5. Alternative Anti‑Emetics
- Ondansetron is considered acceptable for breastfeeding mothers because its physicochemical properties predict low milk transfer, although human milk studies are lacking. 8, 9
- Prochlorperazine has low oral bioavailability and is regarded as compatible with breastfeeding. 8